PhI­II deal­mak­ing fren­zy in i/o con­tin­ues as As­traZeneca fol­lows PA­CIF­IC with a new In­cyte IDO1 com­bo

In­cyte CEO Hervé Hop­penot made it clear a long time ago that he was hap­pi­ly fast and loose about which ap­proved PD-(L)1 drug he part­nered with on his IDO1 drug epaca­do­stat. He launched piv­otal com­bo stud­ies with Mer­ck and Bris­tol-My­ers Squibb, and now he’s kick­ing off a new Phase III tie-up with As­traZeneca’s Imfinzi (dur­val­um­ab) in stage III non-small cell lung can­cer, con­tin­u­ing a re­la­tion­ship that dates back three years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.